Wells Fargo Maintains Equal-Weight on Biogen, Lowers Price Target to $225
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Equal-Weight rating on Biogen (NASDAQ:BIIB) but lowers the price target from $240 to $225.
August 02, 2024 | 6:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Equal-Weight rating on Biogen but lowers the price target from $240 to $225.
The lowered price target from $240 to $225 by Wells Fargo suggests a less optimistic outlook for Biogen's stock performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100